Abstract:Ulcerative Colitis (UC) and Crohn’s disease (CD), the two major types of inflammatory bowel disease (IBD), are chronic diseases with recurrent symptoms and significant morbidity. Long-term persistence of chronic inflammation in IBD is among the major factors contributing to neoplastic transformation and the development of colitis-associated colorectal cancer. There exists a lack of efficient medications for IBD, primarily due to either limited efficacy or side effects. Targeting bromodomain-containing protein 4 (BRD4) represents a novel therapeutic strategy for IBD. Recently, we have successfully identified proprietary, highly potent, and specific BRD4 inhibitors which significantly suppressed the initiation of mucosal inflammation and chronicity in proof-of-concept studies in several animal models of IBD. One of the most pressing challenges in current IBD research is to develop technologies to enable mucosal targeted drug delivery systems that enhance efficacy and decrease side effects. Intriguingly, we found that local delivery of our first-generation BRD4 inhibitors encapsulated in nanoparticles can achieve significantly higher in vivo efficacy at much lower doses than that attained by systemic administration. Local delivery of nanoparticle-encapsulated BRD4 inhibitors by designing nanoparticles that bind to inflamed epithelium would offer superior pharmacotherapy for IBD with higher efficacy, specific delivery, long-lasting release, and a better therapeutic and safety window. We have successfully encapsulated our BRD4 inhibitors in biodegradable nanoparticles with excellent encapsulation efficiency and favorable particle size. Our new generation of BRD4 inhibitors ZL0513, ZL0742, and ZL0591 were encapsulated by a modified solvent displacement method using a polymeric matrix of PEGylated poly (lactic-co-glycolic acid) (PLGA). To evaluate their potential cytotoxic effects, we incubated human colonic epithelial cells (HCECs) and peripheral blood mononuclear cells (PBMCs) with PEGylated-PLGA-ZL0513, ZL0591, and ZL0742 overnight. No apparent increase in cell death was detected in HCECs or PBMCs even at 40 μM. Furthermore, oral administration of our nano-encapsulated BRD4 inhibitors at the dosage of 2 mg/kg effectively block colonic inflammation in both IBD animal models of dextran sulfate sodium (DSS)-induced colitis and oxazolone (OXA)-induced colitis. Collectively, our compelling in vivo efficacy data support that our nano-encapsulated BRD4 inhibitors effectively block colonic inflammation in animal models of IBD. Local delivery of nanoparticle-encapsulated BRD4 inhibitors may offer superior pharmacotherapy for IBD patients. Funding support: Crohn’s & Colitis Foundation Entrepreneurial Investing (EI) Initiative award and Litwin IBD Pioneers Program award from the Crohn’s & Colitis Foundation of America.

Development of BRD4 Inhibitors As Anti-Inflammatory Agents and Antidotes for Arsenicals.

Inhibitors of BRD4 Protein from a Marine-Derived Fungus Alternaria Sp. NH-F6.

The Therapeutic Potential of BRD4 in Cardiovascular Disease

Discovery of Orally Bioavailable Chromone Derivatives as Potent and Selective BRD4 Inhibitors: Scaffold Hopping, Optimization, and Pharmacological Evaluation

Discovery, X-ray Crystallography, and Anti-inflammatory Activity of Bromodomain-containing Protein 4 (BRD4) BD1 Inhibitors Targeting a Distinct New Binding Site

Discovery of Potent and Selective BRD4 Inhibitors Capable of Blocking TLR3-induced Acute Airway Inflammation.

Dual‐target inhibitors of bromodomain and extra‐terminal proteins in cancer: A review from medicinal chemistry perspectives

Efficacy and toxicity analysis of selective BET bromodomain inhibitors in models of inflammatory liver disease

Cutaneous Exposure to Arsenicals is Associated with Development of Constrictive Bronchiolitis in Mice

Drug Discovery Targeting Bromodomain-Containing Protein 4

Development of 4,5-Dihydro-benzodiazepinone Derivatives As A New Chemical Series of Brd4 Inhibitors

Efficacy of Novel Highly Specific Bromodomain-Containing Protein 4 Inhibitors in Innate Inflammation-Driven Airway Remodeling.

NANOPARTICLE-ENCAPSULATED BROMODOMAIN-CONTAINING PROTEIN 4 INHIBITORS FOR THERAPEUTICS OF INFLAMMATORY BOWEL DISEASE

Design, Synthesis and Biological Evaluation of Dihydroquinoxalinone Derivatives As BRD4 Inhibitors.

Design, synthesis and anticancer evaluation of 3-methyl-1H-indazole derivatives as novel selective bromodomain-containing protein 4 inhibitors

Design and Synthesis of MarinePolybrominated Diphenyl Ether Derivatives as Potential Anti‐inflammatory Agents

Design, Synthesis and Biological Evaluation of Novel 6-Phenyl-1,3a,4,10b-tetrahydro-2h-benzo[c]thiazolo[4,5-e]azepin-2-one Derivatives As Potential BRD4 Inhibitors.

Cyclization strategy leads to highly potent Bromodomain and extra-terminal (BET) Bromodomain inhibitors for the treatment of acute liver injury

Drug Discovery of Acetophenone Derivatives As BRD4 Inhibitors

Bromodomain-Containing Protein 4: A Druggable Target.

Development of Small-Molecule BRD4 Degraders Based on Pyrrolopyridone Derivative